Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

OBIOBullishCorporate Developmentsnews

High materiality7/10

Orchestra BioMed advances AVIM and Virtue SAB milestones with funding runway

Aug 10, 2026, 4:15 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Milestones for two programs, FDA Breakthrough Designations, Russell index inclusion, and a funded runway into 2027 collectively suggest potential valuation upside and may attract both speculative and long-only buyers ahead of readouts and continued partnerships.

AI summary

What happened, with direct paths to the underlying reporting

Orchestra BioMed updates on two pivotal cardiovascular programs, with BACKBEAT on track to enroll 284 patients by Q3 2026 and data presentation planned for Q2 2027. Virtue SAB also progresses with site activations. The company holds $110 million in cash, supported by $35 million in strategic capital from Medtronic and Ligand, extending runway into late 2027 and setting up an R&D Day in November.

BACKBEAT targets 284 evaluable patients by Q3 2026; primary data in Q2 2027.
Virtue SAB advancing with site activations and enrollment.
Cash balance $110M; funding from Medtronic and Ligand supports milestones.
R&D Day on Nov 12, 2026; AVIM and Virtue SAB reviews.
Russell index inclusion expands visibility.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.